Richard Edwin Pratley MD

Director, Florida Hospital Diabetes Institute Senior Investigator, Translational Research Institute Adjunct Professor, Sanford-Burnham Medical Research Institute

Join to View Full Profile

2415 N. Orange Ave.Suite 502Orlando, FL 32804

Education & Training

Johns Hopkins UniversityFellowship, Geriatric Medicine (Internal Medicine), 1987 - 1990
University of Michigan Health SystemFellowship, Geriatric Medicine (Internal Medicine), 1986 - 1987
University of MichiganResidency, Internal Medicine, 1983 - 1986
Wayne State University School of MedicineClass of 1983

Certifications & Licensure

FL State Medical License 2011 - 2027
VT State Medical License 2004 - 2012
AZ State Medical License 1993 - 2005
MI State Medical License 1984 - 1989
American Board of Internal Medicine Internal Medicine

Clinical Trials

Impaired Adipogenesis in Insulin Resistance: Pilot Clinical and In Vitro Studies Start of enrollment: 2008 Jan 01
Completed
Pioglitazone Incretin Study Start of enrollment: 2008 May 01
Completed
Phase 4
Bone Turnover in Type 2 Diabetes Patients Start of enrollment: 2008 Aug 01
Unknown status
Phase 4
Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL) Start of enrollment: 2012 Dec 06
ACTIVE_NOT_RECRUITING
Exercise Resistance in Type 2 Diabetes Start of enrollment: 2013 Oct 31
ACTIVE_NOT_RECRUITING
NA
Vitamin D and Type 2 Diabetes Study Start of enrollment: 2013 Oct 01
Completed
Not Applicable
BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects Start of enrollment: 2013 Nov 01
Completed
Phase 1
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) Start of enrollment: 2014 Feb 01
Terminated
Phase 4
Muscle Insulin Resistance in Aging (Mirage)
ACTIVE_NOT_RECRUITING
NA
The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes Start of enrollment: 2018 Mar 08
Completed
ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development) Start of enrollment: 2018 Nov 12
Completed
Not Applicable
Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes Start of enrollment: 2019 Nov 27
ACTIVE_NOT_RECRUITING
GPR119 Agonist for Hypoglycemia in Type 1 Diabetes Start of enrollment: 2021 Apr 21
COMPLETED
PHASE2
REsearching Covid-19 Outcomes in Diabetes (RECODE) Start of enrollment: 2021 Mar 24
ACTIVE_NOT_RECRUITING
Join now to see all

Publications & Presentations

PubMed

Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies.
Medha Munshi, Anna R Kahkoska, Joshua J Neumiller, Anastasia-Stefania Alexopoulos, Nancy A Allen
The Lancet. Diabetes & Endocrinology. 2025-05-01
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A ...
Matthew M Y Lee, Naveed Sattar, Rodica Pop-Busui, John Deanfield, Scott S Emerson
Diabetes Care. 2025-05-01
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.
John B Buse, Steven E Kahn, Vanita R Aroda, Richard J Auchus, Timothy Bailey
Diabetes Care. 2025-04-18

Journal Articles

Lower Rates of Cardiovascular Events and Mortality Associated with Liraglutide Use in Patients Treated with Basal Insulin – A DEVOTE Subanalysis (DEVOTE 10)
John B Buse, Darren K McGuire, Richard E Pratley, Diabetes, Obesity and Metabolism
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients with Type 2 Diabetes at High Risk for Cardiovascular Events: Res...
John B Buse, Richard E Pratley, Diabetes Care
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact and Mechanisms
Richard Pratley, MD, Endocrine Reviews
Trial Design Design and Baseline Characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)
Richard Pratley, Darren K McGuire, ScienceDirect
Join now to see all

Press Mentions

FDA Approves Ozempic for Kidney Disease—Here’s What Doctors Say About Its BenefitsFebruary 6th, 2025
Novo Nordisk Ozempic Get USFDA Nod for Reduction of Kidney Disease Worsening Risk, Cardiovascular Death in Adults with Type 2 Diabetes, Chronic Kidney DiseaseJanuary 29th, 2025
Ozempic Approved for Diabetic Kidney DiseaseJanuary 28th, 2025
Join now to see all

Grant Support

Diabetes RElated to Acute Pancreatitis and its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics (DREAM-ON)PENNSYLVANIA STATE UNIV HERSHEY MED CTR2024–2027
Advanced Insulin Delivery to Reduce Impaired Awareness of Hypoglycemia in a T1D Cohort (AIDRIAHT1C)ADVENTHEALTH ORLANDO2022–2027
Advanced Insulin Delivery to Reduce Impaired Awareness of Hypoglycemia in a T1D Cohort (AIDRIAHT1C)ADVENTHEALTH ORLANDO2022–2027
Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical CentersUNIVERSITY OF FLORIDA2020–2025
Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical CentersUNIVERSITY OF FLORIDA2020–2025
Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical CentersUNIVERSITY OF FLORIDA2020–2025
Impaired Adipogenesis In Insulin Resistance: Pilot Clinical AMP In Vitro StudiesNational Center For Research Resources2010
Clinical Trial: Effects Of Sitagliptin On Bone Turnover In PTS With Type 2 DiabeNational Center For Research Resources2009–2010
Clinical Trial: Effects Of Pioglitazone On Incretin Axis In PTS W Type 2 DiabeteNational Center For Research Resources2009–2010
Impaired Adipogenesis In Insulin Resistance: Pilot Clinical And In-Vitro StudiesNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2010
Natural History Study Of The Development Of Type I DiabetesNational Center For Research Resources2007–2010
Impaired Adipogenesis In Insulin ResistanceNational Center For Research Resources2009
Non-Invasive Glucose Monitoring Using Exhaled Breath CondensateNational Center For Research Resources2008–2009
Weight Loss &AsthmaNational Center For Research Resources2006–2009
Adipose Tissue MCP-1 And MIF: Role In Obesity-Associated InflammationNational Center For Research Resources2007
Adipose Tissue MCP-1 And MIF: Relation To Glucose Tolerance, Insulin ActionNational Center For Research Resources2006
Effects Of Laf237 On MAX Insulin Secretion In PTS With Type 2 DiabetesNational Center For Research Resources2005–2006
Insulin Secretory Defects In PIMA Indians At High Risk For NIDDMNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2000
Cross-Sectional And Longitudinal Study Of "Pre-Diabetes" In The PIMA IndiansNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2000
Cross Sectional And Longitudinal Studies Of Prediabetes In The PIMA IndiansNational Institute Of Diabetes And Digestive And Kidney Diseases1997
Metabolic Function In Elderly HypertensivesNational Institute On Aging1990–1992